Cargando…

Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response

A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal, Lorna, Fehér, Csaba, Richart, Valèria, Torres, Berta, García, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564579/
https://www.ncbi.nlm.nih.gov/pubmed/32764508
http://dx.doi.org/10.3390/vaccines8030442
_version_ 1783595747014344704
author Leal, Lorna
Fehér, Csaba
Richart, Valèria
Torres, Berta
García, Felipe
author_facet Leal, Lorna
Fehér, Csaba
Richart, Valèria
Torres, Berta
García, Felipe
author_sort Leal, Lorna
collection PubMed
description A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials.
format Online
Article
Text
id pubmed-7564579
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75645792020-10-29 Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response Leal, Lorna Fehér, Csaba Richart, Valèria Torres, Berta García, Felipe Vaccines (Basel) Review A functional Human immunodeficiency Virus (HIV) cure has been proposed as an alternative to antiretroviral treatment for life, and therapeutic vaccines represent one of the most promising approaches. The goal of therapeutic vaccination is to augment virus-specific immune responses that have an impact on HIV viral load dynamics. To date, the agreed feature to evaluate the effects of these therapeutic interventions is analytical antiretroviral treatment interruption (ATI), at least until we find a reliable biomarker that can predict viral control. Different host, immunologic, and virologic markers have been proposed as predictors of viral control during ATI after therapeutic interventions. This review describes the relevance of ATI and the different surrogate markers of virological control assessed in HIV therapeutic vaccine clinical trials. MDPI 2020-08-05 /pmc/articles/PMC7564579/ /pubmed/32764508 http://dx.doi.org/10.3390/vaccines8030442 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Leal, Lorna
Fehér, Csaba
Richart, Valèria
Torres, Berta
García, Felipe
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title_full Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title_fullStr Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title_full_unstemmed Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title_short Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
title_sort antiretroviral therapy interruption (ati) in hiv-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564579/
https://www.ncbi.nlm.nih.gov/pubmed/32764508
http://dx.doi.org/10.3390/vaccines8030442
work_keys_str_mv AT leallorna antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse
AT fehercsaba antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse
AT richartvaleria antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse
AT torresberta antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse
AT garciafelipe antiretroviraltherapyinterruptionatiinhiv1infectedpatientsparticipatingintherapeuticvaccinetrialssurrogatemarkersofvirologicalresponse